PRESS RELEASE
ERYTECH announces that Akkadian has initiated
a procedure to obtain the postponement of the vote
of the merger with Pherecydes
Lyon (France), June 5, 2023 – ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical company that develops innovative therapies by encapsulating drugs in red blood cells, announces that Akkadian Partners has initiated a procedure aimed at to obtain the postponement of the vote at the General Meeting on June 23 of the merger with Pherecydes.
The legal proceedings initiated by Akkadian against ERYTECH aim in particular to obtain the postponement of the vote on certain resolutions of the General Meeting scheduled for June 23, 2023 so that Erytech shareholders cannot vote on the merger with Pherecydes.
Akkadian is also requesting the appointment of a legal expert whose mission would be to review the terms of the merger.
Akkadian Partners’ legal action is part of the destabilization campaign they are leading against ERYTECH. To ERYTECH’s knowledge, Akkadian’s stake in the capital of the company was 1,850,000 ERYTECH shares on May 24, 2023, i.e. approximately 5% of the capital.
Erytech intends to obtain the dismissal of this legal action, which it considers to be unfounded, and thus allow its shareholders to vote on the merger with Pherecydes on June 23.
About ERYTECH:
www.erytech.com
ERYTECH is a biopharmaceutical company that develops innovative treatments based on red blood cells to fight against cancers and orphan diseases.
On February 15, 2023, ERYTECH announced its planned strategic merger with PHERECYDES to create a global player in phage therapy. More details are available in the press release.
ERYTECH is listed on the Nasdaq Capital Market in the United States (symbol: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135; symbol: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indices.
For more information, please visit www.erytech.com
CONTACTS
|
ERYTECH Eric Soyer Chief Financial Officer and Director of Operations |
NewCap Mathilde Bohin/Louis-Victor Delouvrier Investor Relations Nicolas Merigeau Media Relations |
+33 (0)4 78 74 44 38 | +33 (0)1 44 71 94 94 |
1
Attachment
20230605_ERYTECH_CP_référé_FR_vf